NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE **HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

Equality impact assessment – Scoping

Eptinezumab for preventing migraine [ID3803]

The i p

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.	
1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No e	quality issues have been identified during the scoping process.
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the committee?
Not applicable.	
3.	Has any change to the draft scope been agreed to highlight potential equality issues?
Not applicable.	
_	
4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.	

Technology appraisals: Scoping

Equality impact assessment for the single technology appraisal of eptinezumab for preventing

migraine

Issue date: June 2022 1 of 2 Approved by Associate Director (name): ...Linda Landells.....

Date: 13 June 2022

Technology appraisals: Scoping

Equality impact assessment for the single technology appraisal of eptinezumab for preventing

migraine

Issue date: June 2022 2 of 2